Chosa Oncology

0,86 SEK

-6,52 %

Mindre end 1K følgere

CHOSA

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Investorkonsensus

-6,52 %

-30,65 %

-53,01 %

+13,98 %

+9,49 %

+15,26 %

-46,59 %

-95,82 %

-93,18 %

Chosa Oncology is a Swedish-Danish biotechnology company that develops solutions for personalized cancer treatment with a focus on diagnostics and drug formulation. The company targets healthcare providers and research actors and works internationally with partners and clinical projects. Chosa Oncology was founded in 2022 and is headquartered in Lund, Sweden.

Markedsværdi

67,85 mio. SEK

Aktieomsætning

39 t SEK

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

26.2

2026

Årsrapport '25

27.5

2026

Generalforsamling '26

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Pressemeddelelse10.11.2025, 09.00

Chosa Oncology AB: CHOSA - Platinum chemotherapy is the backbone of PD-1/PD-L1-based lung cancer therapy

Pressemeddelelse20.10.2025, 10.00

Chosa Oncology AB: CHOSA's presented data on the carboplatin response predictor in breast cancer patients on the ESMO conference

Pressemeddelelse7.10.2025, 13.28

Chosa Oncology AB: CHOSA Wins 2025 Jiangning International Entrepreneurship Contest (Greater Shanghai region), China

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse30.9.2025, 11.03

Chosa Oncology AB: CHOSA announces positive results from a clinical study in collaboration with ETOP/EORTC on platinum predictor in lung cancer

Pressemeddelelse8.8.2025, 06.00

Chosa Oncology AB: CHOSA's presents data on the carboplatin response predictor in breast cancer patients on the annual ESMO conference

Selskabsmeddelelse1.8.2025, 12.29

Chosa Oncology AB: Chosa Oncology's warrants of series TO 2 to be admitted to trading

Selskabsmeddelelse31.7.2025, 15.25

Chosa Oncology AB: Chosa Oncology announces the last day of trading in BTU

Selskabsmeddelelse1.7.2025, 14.19

Chosa Oncology AB: CHOSA extends the timeline for biopsy collection prior to publication from the SPLENDOUR study

Selskabsmeddelelse27.6.2025, 13.48

Chosa Oncology AB: Chosa Oncology announces outcome in rights issue

Selskabsmeddelelse25.6.2025, 10.00

Chosa Oncology AB: Last subscription day in Chosa's subscription period

Selskabsmeddelelse25.6.2025, 07.15

Chosa Oncology AB: CHOSA files new patent application to predict which patients may benefit from platinum chemotherapy and immunotherapy

Selskabsmeddelelse13.6.2025, 11.42

Bulletin from the annual general meeting on 13 June 2025 in Chosa Oncology AB

Selskabsmeddelelse12.6.2025, 06.45

The subscription period in Chosa Oncology AB's rights issue begins today - the company invites to a webcast presentation

Selskabsmeddelelse10.6.2025, 14.04

Chosa Oncology AB publishes information document in connection with rights issue of units

Pressemeddelelse9.6.2025, 14.51

Chosa Oncology AB: CHOSA Oncology invites investors to two upcoming presentations

Selskabsmeddelelse2.6.2025, 06.45

Chosa Oncology AB resolves on a directed issue of units and on a rights issue of units to provide funds for reaching several value-enhancing milestones

Selskabsmeddelelse13.5.2025, 12.48

Notice of annual general meeting in Chosa Oncology AB

Selskabsmeddelelse9.5.2025, 13.44

Chosa Oncology AB: CHOSA- Extending CHOSA's Platin DRP: Predicting Carboplatin Efficacy in Breast Cancer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.